Tubulin-targeting agent combination therapies: dosing schedule could matter
1Institut Gustave Roussy, Villejuif cedex, France. eric.solary@igr.fr
Unlabelled:
Tubulin-binding agents are potent cytotoxic drugs that are largely used to treat haematological malignancies and solid tumours. In this issue of British Journal of Pharmacology, doxorubicin was shown to decrease the activity of vincristine when administered simultaneously, unless cell cycle arrest mechanisms were disrupted. This observation emphasizes the need to better explore schedule-dependent antagonist effects in anticancer drug combination therapies.
Linked Article:
This article is a commentary on the research paper by Ehrhardt et al., pp. 1558-1569 of this issue. To view this paper visit http://dx.doi.org/10.1111/bph.12068.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Dosage Regimen: Individualization
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
